Cantor Fitzgerald Reiterates Overweight on Seelos Therapeutics, Maintains $2 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Seelos Therapeutics (NASDAQ:SEEL) and maintained a $2 price target.
June 23, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Seelos Therapeutics and maintained a $2 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Seelos Therapeutics. The maintained $2 price target suggests that the stock is expected to perform well in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100